Lonza and Selecta Biosciences (SELB) Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy – StreetInsider.com
|
Lonza and Selecta Biosciences (SELB) Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy
StreetInsider.com Under the terms of the agreement, Lonza will produce an Anc80-AAV-based gene therapy product for Selecta's proprietary program for the treatment of Methylmalonic Acidemia (MMA), a rare inborn error of metabolism, and may in the future produce other … |
